Tumor Antigen-Specific T and B Cell Immune Monitoring
Evaluating responses to tumor-associated antigens is essential for cancer vaccines, TCR therapies, and checkpoint inhibitor programs. Accelevir offers tumor antigen-specific immune assays to measure functional T and B cell activity against defined neoantigens or shared tumor targets.
Technical Capabilities:
- ELISpot/ICS for neoantigen-specific T cell responses.
- Flow cytometry for tumor antigen-specific B cell frequency and phenotype.
- Cytokine multiplex to define immune polarization.
- Support for peptide, protein, and whole-cell antigen formats.
Why Partner with Accelevir:
- Proven expertise in oncology immunogenicity studies.
- Integration with tumor mutational burden and sequencing data.